Alexander Spira, MD, PhD, Discusses Safety and Efficacy of Mobocertinib in EGFR ex20ins+ NSCLC Following Prior EGFR TKIs

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about clinical benefits of using mobocertinib in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how mobocertinib led to antitumor activity in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC) who were treated in a phase 1/2 study (NCT02716116) following prior tyrosine kinase inhibitor (TKI) therapy.


This is a subset analysis of a study of mobocertinib that has been going on for quite some time. It started as a phase 1 study, and this looked at a specific population of patients who got prior TKI therapy against [EGFR] exon 20. [Prior therapy] included experimental drugs, [such as] afatinib [Gilotrif], osimertinib [Tagrisso], and other [EGFR] exon 20 drugs like poziotinib. [The goal of the study was to] see how well [patients] did when they were treated with mobocertinib.

What we learned from this study is that patients who got prior TKI were able to benefit from mobocertinib, which was good news. Some of these TKIs were specific against [EGFR] exon 20, such as poziotinib, while others were not necessarily [EGFR] exon 20 specific, but more broad TKIs such as afatinib or osimertinib. My take home on this is that there is at least some evidence of efficacy of mobocertinib in patients who got other TKIs prior [to treatment] so we’re hoping that mobocertinib serves as a best in class compared to the other TKIs that are out there.


Spira A, Ramalingam SS, Neal J, et al. Mobocertinib in EGFR exon 20 insertion-positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Abstract OA15.01.

Related Videos
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Related Content